Bloodstream infection by two subpopulations of Klebsiella pneumoniae ST1685 carrying KPC-33 or KPC-14 following ceftazidime/avibactam treatment: considerations regarding acquired heteroresistance and choice of carbapenemase detection assay

Abstract excerpt

Sir, Ceftazidime/avibactam, a novel β-lactam/β-lactamase inhibitor combination, is currently approved for the treatment of KPC-producing Enterobacterales infections. However, mutations in the β-lactamase gene, especially at key residues in the active site, increase ceftazidime/avibactam MIC values leading to the emergence of resistant strains.1 Strains harbouring KPC-3 or KPC-2 mutations in the Ω-loop have been...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antibiotic Resistance in Bacteria
• Share to Antibiotics Pharmacokinetics and Efficacy